2017
DOI: 10.1016/j.neuropharm.2016.10.019
|View full text |Cite
|
Sign up to set email alerts
|

Novel, highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
25
0

Year Published

2017
2017
2020
2020

Publication Types

Select...
5
2

Relationship

3
4

Authors

Journals

citations
Cited by 34 publications
(27 citation statements)
references
References 59 publications
2
25
0
Order By: Relevance
“…The GABA signal pathway performs two functions: synthesis and transport of GABA, and synaptic and non-synaptic release of GABA [14]. The synaptic release of GABA is related to certain proteins such as GAD-65, GAD-67 and GABA-T, which are responsible for converting glutamate to the GABA [15,16]. The transport of GABA neurotransmitter is related to GABA transporters such as GAT-1, GAT-1, GAT-1 and GAT-3, which belong to the solute carrier 6 genes family A (SLC6A) of Na + -dependent transporters [17].…”
Section: Discussionmentioning
confidence: 99%
“…The GABA signal pathway performs two functions: synthesis and transport of GABA, and synaptic and non-synaptic release of GABA [14]. The synaptic release of GABA is related to certain proteins such as GAD-65, GAD-67 and GABA-T, which are responsible for converting glutamate to the GABA [15,16]. The transport of GABA neurotransmitter is related to GABA transporters such as GAT-1, GAT-1, GAT-1 and GAT-3, which belong to the solute carrier 6 genes family A (SLC6A) of Na + -dependent transporters [17].…”
Section: Discussionmentioning
confidence: 99%
“…So far, tiagabine ( 2 ) is the only GAT1‐selective GABA uptake inhibitor in clinical use and it was approved as add‐on treatment of partial‐onset seizures . Furthermore, several experimental GAT1 inhibitors such as SK&F‐89976A ( 3 ), NO711 ( 4 ), and DDPM‐2571 ( 5 ) have been synthesized and characterized with respect to their biological activities including anticonvulsant, anxiolytic, antidepressant, and antinociceptive effects . GAT1‐selective inhibitors are usually derivatives of small cyclic amino acids, particularly nipecotic acid ( 6 ) or guvacine ( 7 ).…”
Section: Introductionmentioning
confidence: 99%
“…These small cyclic amino acids, 6 and 7 , already possess reasonable inhibitory potency toward GAT1 in vitro, but due to their polarity they have limited blood–brain barrier permeability and display hardly any anticonvulsant effects in vivo . The substitution of the amino group of the cyclic amino acids 6 or 7 with a spacer and an aromatic residue is a common approach to increase lipophilicity and to improve the capability of crossing the blood–brain barrier and thus to obtain compounds such as 2 – 5 that mediate potent anticonvulsant effects in vivo …”
Section: Introductionmentioning
confidence: 99%
“…1) is a classical anticonvulsive drug used for treating epileptics in clinics, and is widely used in the United States, Europe and other countries. 1,2 It selectively increased the concentration of g-aminobutyric acid in presynaptic neurons and glial cells for effective therapy. Besides, it has been utilized to treat anxiety disorders, panic disorders, posttraumatic stress disorders, as well as neuropathic pain.…”
Section: Introductionmentioning
confidence: 99%